Stromal Amyloid β drives Neutrophil extracellular trap formation to augment tumour growth by Munir, Hafsa et al.
 1 
Stromal Amyloid β drives Neutrophil extracellular trap formation to 
augment tumour growth 
 
Authors: Hafsa Munir1, James O. Jones1,2, Tobias Janowitz3,4,5, Carla P. Martins1, Sarah J. 
Welsh2, Jacqueline D. Shields1*. 
1MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Box 197 
Cambridge Biomedical Campus, Cambridge, CB2 0XZ.  
2Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, 
Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0QQ. 
 
3Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, NY 11724, United States of 
America 
 
4Northwell Health Cancer Institute, New York, NY 11021, United States of America. 
 
5Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, 
Cambridge CB2 0RE, United Kingdom. 
*Correspondence to: js970@mrc-cu.cam.ac.uk. 
 
Running Title: Amyloid β-dependent stromal crosstalk drives tumor-induced NET formation. 
 
Abstract: Tumors are comprised of cancer cells and a network of non-cancerous stromal 
cells. Cancer-associated fibroblasts (CAFs) are well known to support tumorigenesis and are 
emerging as immune modulators. While many leukocyte populations are well studied in 
cancer, neutrophils have received less attention. Neutrophils can release histone-bound 
nuclear DNA and cytotoxic granules as extracellular traps (NETs) in a process termed 
NETosis. Here, we show that CAFs induce formation of NETs both within the tumor 
microenvironment and at systemic levels in the blood and bone marrow. These tumor-induced 
NETs (t-NETs) are driven by a ROS-mediated pathway dependent on PAD4 and CD11b. 
Remarkably, CAF-derived Amyloid β was identified as the key factor driving t-NETosis, a 
protein with significance in both neurodegenerative and inflammatory disorders. Therapeutic 
inhibition of NETs in established tumors prevented growth, skewing neutrophils to a pro-
inflammatory phenotype. Reciprocally, t-NETs enhanced CAF activation phenotypes. 
Mirroring murine observations, NETs were detected juxtaposed to CAFs in human melanoma 
and pancreatic adenocarcinoma, and elevated expression of amyloid and β-Secretase 
correlated with poor prognosis. In summary, we report the existence of cross-talk between 
CAFs and neutrophils within the tumour microenvironment whereby CAF-induced t-NETosis 
supports cancer progression, identifying Amyloid β as the protagonist and potential 
therapeutic target. 
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Significance: This study defines the existence of a pro-tumor immunomodulatory function of 
the stroma showing the induction of Neutrophil Extracellular Traps through CAF-derived 
Amyloid β. We term this novel process “Tumor-induced NETosis” (t-NETosis) and propose 
that therapeutic inhibition of this mechanism, which we observe in human melanoma and 
pancreatic cancer, has the potential to improve patient outcome.  
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Introduction 
The tumor microenvironment comprises a complex niche of cancer cells and “normal” cell 
populations collectively referred to as the stroma. The stroma includes leukocytes, cancer-
associated fibroblasts (CAFs), pericytes, blood vessels and lymphatic vessels 1. Tumor 
development is accompanied by changes in the phenotype, function and interactions between 
these stromal constituents 2–5, a process which is central to carcinogenesis. 
 
 
CAFs are one of the most abundant stromal populations in the tumor, and display considerable 
heterogeneity and plasticity 6. Multiple tumour promoting functions have been attributed to 
CAFs, including promoting angiogenesis, remodelling extracellular matrix 7,8, modifying tumor 
stiffness 9,10, nutrient processing 11 and facilitating the invasion of tumor cells 1,4. More recently, 
CAFs have emerged as modulators of the innate and adaptive immune responses as they are 
recruited to the tumor. CAF-derived factors have been shown to drive the recruitment and M2 
polarization of macrophages 12. CAFs drive T-cell deletion and exhaustion in an antigen-
dependent manner by FASL and PD-L2 mediated interactions 5. CAFs also mediate exclusion 
of T-cells from tumors via production of CXCL12 2. Furthermore, CAF-derived IL-6 can induce 
systemic immunosuppressive effects 13. Collectively, these data demonstrate that anti-cancer 
immune responses can be modulated by CAFs, and failure of the immune system to control 
cancer is not solely mediated by cancer cells but also the surrounding stroma. 
 
 
Neutrophils are the most abundant circulating leukocyte population, functioning as early 
responders to inflammatory insult 14. Following activation, neutrophils utilize several 
mechanisms to exert their effects, such as secreting inflammatory factors that influence other 
immune populations, production of reactive oxygen species (ROS) and cytotoxic granular 
proteins to eliminate pathogens, as well as releasing extracellular traps (NETs). NETs are 
composed of chromatin bound DNA decorated in cytosolic and granular proteins such as 
myeloperoxidase (MPO) and neutrophil elastase (NE) 14. Though the molecular mechanisms 
governing NET release are still not completely understood, in certain contexts it requires ROS-
mediated, calcium driven citrullination of histones by Protein Arginine Deiminase 4 (PAD4) 14.  
 
 
NETs detected in chronic inflammatory disorders exert their pro-inflammatory effects by 
modulating the activity of other stromal populations at the site of tissue damage. In murine 
models of inflammation, such as systemic lupus erythematosus, NETs activate plasmacytoid 
dendritic cells through engagement of TLR9, thus exacerbating the condition 15,16. In addition, 
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NETs have been shown to reduce the threshold for the activation of CD4+ T-cells in response 
to antigen 17. As well as regulating immune cells, NET-derived components were found to 
induce activation of lung fibroblasts in a lung fibrosis model, promoting their differentiation into 
myofibroblasts 18. Subsequent collagen deposition, proliferation and migration of the 
differentiated myofibroblasts was also enhanced by treatment with NETs 18. 
 
 
While the roles of neutrophils in infection have been well established, their contribution to 
tumor progression, immune evasion and metastasis remains controversial. Indeed, 
neutrophils have been reported to exert both anti- and pro-tumorigenic effects depending on 
the environmental cues to which they are exposed 19,20. This plasticity has made it difficult to 
ascertain the spatial and temporal nature of neutrophil functions within tumors. Neutrophil-
derived NETs have been identified as modulators of cancer-induced thrombosis through a 
granulocyte-colony stimulating factor (G-CSF) dependent mechanism 21 and facilitate 
metastasis by capturing circulating tumor cells to promote colonization of distal sites 22–25. 
They have also been detected in several blood cancers 26–28 and recently, NET-mediated 
remodelling of the extracellular matrix has been reported to awaken dormant cancer cells and 
promote aggressive lung metastasis 29. While observed in primary tumors, the contribution of 
NETs to tumorigenesis and underlying mechanisms are lacking 22,30–34. 
 
 
Here, we report the existence of a previously undescribed crosstalk between CAFs and 
neutrophils driving a phenomenon termed Tumor-induced NETosis (t-NETosis). In three 
different models of cancer we show that CAF-secreted Amyloid β drives formation of t-NETs 
through CD11b in a ROS-dependent, PAD4-driven mechanism both within the 
microenvironment and at systemic levels in the blood and bone marrow. Therapeutic inhibition 
of PAD4 stopping t-NETosis, or prevention of Amyloid β release abolished growth of 
established tumors and restored a pro-inflammatory-like status indicating a potential axis to 




While neutrophils are observed in tumors, little is known about how micro-niches created by 
stromal compartments perturb the activity of these immune cells. In primary murine pancreatic 
and skin (melanoma) tumors we observed that neutrophils were frequently confined to CAF-
rich regions (Figure 1A) implying a potential for cross-talk between the two populations.  
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Influence of CAF-derived factors on neutrophil function 
To determine if CAF-derived factors have the capacity to impact aspects of neutrophil 
behavior, we first treated bone marrow-derived neutrophils with conditioned media (CMed) 
from CAFs, tissue-matched normal FBs, or Phorbol 12-myristate 13-acetate (PMA; a well-
known activator of neutrophils) and assessed viability, surface activation markers, ROS 
production and phagocytic capability of the neutrophils. Isolated CAFs were characterised  
based on surface expression of classic markers; Thy1, Podoplanin and PDGFRα 
(Supplementary figure 1A) and lack of immune (CD45) and epithelial (EpCAM) markers 
(Supplementary Figure 1A). Lung and pancreatic FB or CAF CMed had no impact on 
neutrophil viability for the duration of treatment while PMA induced significant neutrophil death 
(Supplementary Figure 1B).  Expression of activation markers (CD11b and CD18) tended to 
increase in response to lung CAF CMed treatment (Supplementary Figure 1C) in the presence 
or absence of an additional inflammatory insult (Lipopolysaccharide; LPS). CAF CMed failed 
to induce ROS production in neutrophils (Supplementary Figure 1D) nor did the cells exhibit 
enhanced phagocytic capabilities (Supplementary Figure 1E) relative to PMA after 30min 
treatment. Therefore, the classical functions of neutrophils 14 were largely unaltered by 
treatment with CAF-derived factors in vitro. 
 
CAF-derived factors induce NETs in primary tumors 
Having already observed neutrophils in proximity to CAF-rich regions, we also detected the 
presence of NETs within primary murine pancreatic and skin tumors (Figure 1B). NETs were 
defined as staining positive for extracellular DNA, MPO and Citrullinated histone H3 (CitH3). 
We termed these structures tumor-induced NETs (t-NETs), and thus sought to examine the 
role of t-NETs in the primary tumor, focusing on the mechanisms driving their release. 
 
To determine if CAF-derived factors drive generation of t-NETs, we treated isolated bone 
marrow neutrophils with CAF or FB CMed and analyzed NETosis (Supplementary Figure 2A, 
B and Supplementary Movie 1). While CMed from normal FBs was unable to induce NETs, 
CAF CMed from pancreatic, lung and skin tumors was sufficient to induce NETosis to levels 
comparable with PMA (Figure 1C and Supplementary figure 2B). As NETosis is thought to be 
largely a “suicidal” process 14, we next quantified neutrophil death following longer-term 
exposure to CAF CMed (compared to 30min treatment in Supplementary Figure 1B). After 3h 
of treatment with CAF CMed, a trend of increasing cell death was observed compared to 
untreated neutrophils and to levels comparable with PMA (Figure 1D). This was confirmed by 
staining of NETting neutrophils with live/dead dye (Figure 1E) indicating that CAF-influenced 
NETosis is a cell-death dependent effect. As autophagy has also been implicated as a mode 
of death in NETosis 34, we then quantified the level of NETosis in the presence of chloroquine, 
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an inhibitor of autophagy. Chloroquine did not rescue the neutrophils from undergoing 
NETosis (Supplementary figure 2C) ruling out autophagy as a mechanism underlying CAF-
induced t-NET formation.  
 
G-CSF and intracellular ROS have been reported to induce citrullination of Histone H3 which 
is required for NET formation 35. Thus, to determine if CAF-derived factors stimulate t-NETs 
in a ROS-dependent manner, we first inhibited ROS production. Pre-treatment of neutrophils 
with N-acetylcysteine (NAC; Figure 1F) Diphenyleneiodonium (DPI), Vitamin C or Trolox 
(Supplementary figure 2D-F) prior to CAF CMed treatment suppressed NET formation, 
indicating that ROS production by neutrophils in response to CAF-derived factors is a key 
mediator in the process. However, unlike previous reports which showed that tumor-derived 
G-CSF drives NETosis systemically, here CAF-mediated NETosis was not driven by G-CSF 
as NET release was not significantly reduced following neutralization of G-CSF in vitro (Figure 
1G). Together, these data suggest that CAFs are key drivers of ROS-dependent, suicidal t-
NETosis and the potential factors that induce t-NETs in this context are likely distinct from 
those previously reported 21,34.  
 
CAF-derived factors induce systemic effects on neutrophils  
We next investigated whether CAF-derived factors could render circulating neutrophils more 
susceptible to NETosis before being recruited into the tumor. Indeed, we observed that bone 
marrow-derived neutrophils isolated from pancreatic, lung and skin tumor-bearing mice 
displayed a greater propensity to generate t-NETs in the absence of an additional stimulus 
compared to neutrophils from non-tumor bearing mice (Figure 2A). With pancreatic tumors, 
but not for either lung or skin, this was accompanied by an increase in neutrophil death in the 
bone marrow (Supplementary Figure 3A). However, there was not a significant increase in the 
number of neutrophils isolated from tumor bearing mice (Figure 2B).  
 
To determine whether CAF-derived factors were sufficient to drive the observed susceptibility 
of bone marrow-derived neutrophils towards NETosis, we intravenously (I/V) infused CMed 
from pancreatic or lung-derived FBs or CAFs in the absence of tumors. Spontaneous NET 
production by bone marrow-derived neutrophils ex vivo was significantly enhanced in mice 
treated with CAF CMed compared to FB CMed or basal media (Figure 2C) with concurrent 
increases in neutrophil death (Supplementary Figure 3B) and counts (Figure 2D). Such 
increases in neutrophil number following CAF and FB CMed infusion indicates that FB and 
CAFs may be a source of other factors, such as G-CSF, in tumor bearing mice, which would 
be consistent with a previous report showing increases in neutrophil number in patients due 
to higher levels of G-CSF 21. The discrepancy between the neutrophil counts after I/V infusion 
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of the CMed compared to those in the tumor bearing mice is potentially because the 
concentration of factors that drive neutrophil expansion may be higher in the in vitro CAF 
cultures compared to the amount secreted by the tumor stroma. Together, these data suggest 
that CAFs can skew neutrophils towards NET formation before they enter the tumor. 
 
CAF-driven t-NETs are pro-tumorigenic 
Having shown that CAFs can promote t-NETosis at local and systemic levels we next sought 
to determine the functional impact of the t-NETs on primary tumor development. Previous 
studies have analyzed the effect of neutrophil depletion on tumor progression, primarily by 
using anti-Ly6G antibodies 36–38, however when studying NETosis this approach would have 
confounding effects as a result of their depletion. Therefore, to disrupt NETosis without 
impacting other neutrophil functions we inhibited PAD4, a key component of the NET pathway, 
driving citrullination of histones to facilitate DNA release 14. To first ascertain the requirement 
of PAD4 in CAF-driven NETosis, we tested the effects of its inhibition on neutrophils in vitro. 
A complete suppression of CAF CMed-induced NET release was observed in neutrophils 
treated with the PAD4 inhibitor, Cl-amidine, in vitro (Figure 2E). Moreover, treatment with Cl-
amidine in vivo prior to I/V infusion of lung CAF CMed was sufficient to abolish NET release 
by bone marrow-derived neutrophils along with a reduction in neutrophil death ex vivo (Figure 
2F and Supplementary Figure 3C). The number of bone marrow neutrophils was largely 
unaffected (Figure 2G) suggesting that NETosis was inhibited without influencing other factors 
driving an increase in neutrophil number.  
 
In vivo, mice with established skin tumors were treated with GSK484, Cl-amidine (PAD4 
inhibitors) or DMSO for 7 days (Figure 3A). Cl-amidine (Supplementary Fig 4A) treatment 
completely inhibited tumor growth compared with vehicle controls and this effect was 
replicated by treatment with the more specific PAD4 inhibitor, GSK484 (Figure 3B). While 
tumor volumes were drastically different following inhibition of t-NETosis, we did not observe 
a significant effect on tumor immune infiltrates and resident stroma by flow cytometry profiling 
(Figure 3C and supplementary figure 4B, C and E). Importantly, the number of neutrophils 
recruited to tumors was unaffected by PAD4 inhibition indicating that treatment effects on 
neutrophil behavior were specific to NETosis (Figure 3C, D and supplementary figure 4B). 
Suppression of tumor growth was not due to direct toxicity of the small molecule inhibitors on 
cancer cells. Indeed, treatment with GSK48, had no effect on the growth of melanoma cells in 
vitro (Supplementary figure 4F), while treatment with Cl-amidine only mildly affected cell 
growth (non-significant; Supplementary figure 4F) which could be a potential consequence of 
the broader action of Cl-amidine. Therefore, the effect of inhibiting PAD4 on the tumor growth 
in vivo was primarilty due to inhibition of NETosis. 
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With the knowledge that circulating neutrophil-derived NETs have been reported to contribute 
to thrombus formation in advanced disease we also examined the plasma of mice treated with 
PAD4i. GSK484, but not Cl-amidine treatment was accompanied by lower levels of the clotting 
factors von willebrand factor (vWF), while the levels of fibrinogen were unchanged (Figure 3E 
and Supplementary figure 4D) suggestive of a reduction in NET-mediated thrombosis within 
the circulation of treated mice. 
 
Since the anti-tumor effects of t-NET inhibition were not directed by secondary effects on other 
infiltrating immune populations, we then examined the neutrophils themselves in more detail. 
Following treatment with CAF CMed and PAD4 inhibitor for 3h in vitro to prevent NETs, 
neutrophils increased expression of activation markers CD11b and CD18, and completely 
shed surface CD62L (Figure 3F), typical of activated neutrophils. Phagocytosis was reduced 
and intracellular ROS levels were exhausted, consistent with depletion following an oxidative 
burst (Figure 3G and H). Furthermore, neutrophils exhibited enhanced degranulation with 
increasing expression of surface CD35 and CD63 after PAD4 inhibition associated with a pro-
inflammatory phenotype (Figure 3I). To test the pro-inflammatory, anti-tumour potential of 
degranulation following PAD4 inhibition, tumor cells were incubated in media from control or 
PAD4i-treated neutrophils that had been stimulated with CAF CMed. Media components from 
PAD4-inhibited neutrophils significantly impaired tumor cell growth compared to control 
conditions (Figure 3J). Together these data support the concept that t-NETs are pro-
tumorigenic, and their inhibition is sufficient to prevent growth of established tumors through 
the restoration of an inflammatory state in tumor-infiltrating neutrophils. 
 
The success of PAD4 inhibition in melanoma was not recapitulated in pancreatic tumors, with 
no significant changes in tumor volume being observed after treatment (Supplementary Figure 
5A and B). However, systemic effects were detected, with PAD4 inhibition reducing the levels 
of clotting factors in the plasma (Supplementary Figure 5C) as with melanoma. Similarly, no 
significant changes in the stromal landscape within the tumor were detected (Supplementary 
figure 5D and E). We suggest that the lack of impact on these tumors, which still contained t-
NETs (Figure 1B), may be due to the lack of drug penetration into the tumor which is a well-
known  phenomenon in mouse and human pancreatic cancer 39,40. However, treatment was 
effective as we observed reduced systemic clotting factors after PAD4 inhibition. 
 
CAF-derived Amyloid β drives t-NET formation 
As neutrophils within the tumor traverse CAFs before entering the main tumor bulk, we next 
assessed whether direct contact was required for NET generation, or whether it was entirely 
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soluble-mediator dependent as we observed systemically. To evaluate the capacity of CAFs 
to induce NETs by direct cell-cell interaction vs. secreted factors, neutrophils were seeded 
onto pancreatic tumor-derived CAFs in the presence or absence of FB or CAF CMed. While 
CAFs in the presence of CAF CMed readily induced NETosis, CAFs with normal FB media 
could not (Figure 4A). This suggested that direct contact between CAFs and neutrophils was 
not sufficient to drive t-NETosis, and the effect is primarily mediated through factors secreted 
by the CAFs.  
 
Therefore, we performed proteomic analysis of the pancreatic FB and CAF CMed to identify 
the potential t-NET driver(s). Mass spectrometry revealed a number of differentially secreted 
proteins (Figure 4D and Supplementary figure 6) between these two cell types. Of interest, 
Amyloid β A4 protein (APP), fibronectin and heat shock protein 90 were significantly 
upregulated in CAF CMed (Figure 4E), all of which have been implicated in NETosis in 
different disease contexts 41–44. Treatment of neutrophils with a fibronectin inhibitor had no 
effect on the ability of CAF CMed to induce NETs (Supplementary figure 7A) thus we 
examined APP in greater detail. Similar to studies implicating Amyloid β peptide driven 
NETosis in Alzheimer’s 45, APP mRNA was detected in pancreatic CAFs at higher levels than 
pancreatic stellate cells (Supplementary figure 7B) and this was maintained at the protein level 
with Amyloid β detected in CAF CMed (Figure 4F). Upon determining that recombinant 
Amyloid β but not Amyloid α was able to induce NETosis in treated neutrophils in a dose 
dependent manner (Supplementary figure 7C) we next assessed whether Amyloid β was 
present in NET-rich tumors. In pancreatic tumors, two distinct patterns of APP distribution 
were observed with regions displaying either diffuse or punctate staining that co-localized with 
CAFs and tumor cells (Figure 4G) consistent with Amyloid β aggregates observed in other 
diseases. These data suggest that CAFs are a source of Amyloid β in the tumor, a key driver 
of NETosis. 
 
To confirm that it was Amyloid β within CAF CMed that was responsible for the observed 
effects on neutrophils we inhibited the β-secretases which regulate secretion of Amyloid β 
(BACE 1-2). BACE inhibition in pancreatic and lung CAFs abolished the ability of the CMed to 
induce NETs in vitro (Figure 4H) supporting the hypothesis that Amyloid β production by CAFs 
underlies their capacity to induce t-NETs. A trend towards reduced neutrophil death was also 
observed in the absence of Amyloid β (Supplementary Figure 8A) indicating that ROS-
mediated, suicidal NETosis in the tumor context is potentially driven by a single CAF-derived 
factor. 
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To further support our observations, I/V infusion of CAF CMed derived from CAFs pre-treated 
with BACE inhibitor to suppress Amyloid β production, abolished the systemic effects 
measured with CAF CMed (Figure 4I and Supplementary Figure 8B), whilst the effect of CAF 
CMed in vivo was recapitulated by infusion of recombinant Amyloid β alone (Figure 4I). We 
next examined the effects of BACE inhibition in vivo in skin tumour bearing mice (Figure 4J) 
using the same treatment regime as Cl-amidine and GSK484. As with inhibitors of NETosis, 
disruption of Amyloid β secretion prevented further increases in tumor volume compared with 
vehicle controls (Figure 4J), implying that CAF-driven Amyloid β-mediated NETosis supports 
tumour development in vivo, and that perturbation of either the NET driver or NET process is 
sufficient to prevent growth. This was confirmed using the B16.F10 melanoma model which is 
both neutrophil and NET poor 35. Treatment with CAF CMed or recombinant Amyloid β 
increased tumor growth (Figure 4K), potentially coinciding with enhanced infiltration of 
NETting neutrophils (Supplementary Figure 8D). 
 
We then considered how CAF-derived Amyloid β may exert its effects on neutrophils. In light 
of reports that CD11b may act as a receptor for Amyloid β 46, we blocked CD11b during CAF 
CMed treatment and found that it completely abolished NETosis (Figure 4L and 
Supplementary Figure 8C) without affecting other functions such as phagocytosis (data not 
shown). In contrast, TLR2 neutralization on CAF CMed treated neutrophils had no effect on 
their capacity to NET (Figure 4M and Supplementary Figure 8C). Thus, CD11b on the surface 
of neutrophils may indeed function as a receptor, with its blockage desensitizing cells to the 
effects of Amyloid β present in CAF CMed.   
 
 
NETs reciprocally activate CAFs  
Whilst we observed that t-NETosis was entirely soluble mediator driven (Figure 4A), the fact 
that NETs observed in the primary tumor site were often restricted to CAF dense regions 
(Figure 1A) led us to ask if t-NETs had reciprocal, pro-tumor effects on the phenotype and 
function of CAFs in their proximity. Treatment of CAFs with NETs supported an enhanced 
proliferation of CAFs (Figure 5A), and induced features of activation in vitro (Figure 5 B-E).  
 
We observed an increase in contraction of CAFs by the appearance of large gaps between 
CAFs treated with NETs derived from CAF CMed treated neutrophils compared to FB treated 
with NETs which remained as a monolayer (Figure 5B). To assess the contractile properties 
of the CAFs after treatment with t-NETs, we performed contraction assays. t-NET treated 
CAFs contracted collagen gels to a greater extent than CAFs treated with unstimulated 
neutrophil-derived NETs (Figure 5C), and coincided with an increased expression of αSMA 
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and Col1a2 at the RNA and protein level (Figure 5D and E respectively). Examination of 
tumors treated with either PAD4 or BACE inhibitors revealed a reduced cellularity per unit 
volume when compared with vehicle treated tumours (Figure 5F and G). Moreover, consistent 
with earlier observations NET inhibition promoted degranulation and impaired tumor cell 
growth (Figure 3I and J), a similar effect was mirrored in CAFs (Figure 5H). Fibrotic structures 
with more mature collagen made up the remaining tumor mass (Figure 5G lower panel). 
Collectively, these data suggest that neutrophils skewed to undergo NETosis likely localise to 
CAF rich regions of a tumor where they form t-NETs in response to Amyloid β, promoting CAF 
expansion, contractility and deposition of matrix components supportive of tumor growth. 
 
Conservation of Amyloid β-NET axis in human disease 
Having observed a significant pro-tumor communication between CAFs and neutrophils in 
multiple murine models, we sought to determine the clinical significance of these findings by 
examining human tumors. T-NETs were observed in human pancreatic tumors (Figure 6A), 
melanoma and melanoma metastases (Figure 6B and Supplementary Figure 9a), and when 
detected, both NETs and neutrophils were found juxtaposed to CAFs mirroring murine tumors. 
We next examined publicly available datasets for APP and β-secretase. Significantly, both 
pancreatic adenocarcinoma and cutaneous melanoma expressed elevated levels of APP and 
BACE2 compared to matched normal tissue (Figure 6C and D). When detected, elevated 
levels of Amyloid β could be measured circulating in the blood of patients with advanced 
melanoma compared with heathy controls (Supplementary Figure 9b). Moreover, expression 
of both app and bace2 strongly correlated with stromal markers pdpn, acta2, col1a2, cd34 
typically used to identify CAFs, but not lymphatic marker lyve-1 (Figure 6E) inferring that 
correlations were specific to CAFs and not other components of the tumor stroma. These data 
recapitulate murine tumours, supporting CAFs as a source of Amyloid β in human pancreatic 
cancer and melanoma. The high expression of bace2, the rate-limiting step in Amyloid β 
release, rather than app was correlated with poorer patient prognosis in both tumor types 
(Figure 6F and G). Collectively, these findings suggest that Amyloid β secreted by CAFs is a 
critical driver of t-NET formation conserved in human cancers associated with poor prognosis, 
and importantly, has the potential to be detected in liquid biopsies.  
 
Discussion 
The stroma is critical to tumour development and progression and it is evident that targeting 
stromal interactions offers many opportunities for cancer treatments 1. Here, we report the 
existence of a previously undescribed pro-tumor crosstalk between non-immune and immune 
stromal components to support growth. We demonstrate that neutrophils recruited to the tumor 
frequently localize to cancer-associated fibroblast (CAF)-rich areas, where they are stimulated 
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to generate extracellular traps (NETs) supporting tumor growth. This process, which we have 
termed tumor-induced NETosis (t-NETosis), is driven by CAF-secreted Amyloid β both locally 
via CD11b on neutrophils within the primary tumor and at the systemic level within the bone 
marrow niche.  
 
While neutrophil function has been extensively studied in the context of inflammation and 
tissue damage 47–49, there have been fewer studies relating to their contribution to the primary 
tumor 32,50,51 as well as the role of NETs and mediators responsible for driving their release 
21,51. Contradictory studies have reported NET-derived proteins acting to both promote tumor 
cell proliferation and invasion 52,53, as well as inhibit tumor growth through apoptosis induction 
32,54. In advanced disease, NETs have been reported to contribute to thrombus formation 21, 
metastatic colonization 22,23 and most recently the reactivation of dormant tumor cells 29. 
Previous studies point to a central role for G-CSF in recruiting neutrophils and to date is the 
only factor that has been identified as a NET inducer 21,35. This is particularly thought provoking 
given that cancer patients that are at high risk of becoming neutropenic receive G-CSF therapy 
in an attempt to restart myelopoiesis after chemo- and radiotherapy 55. Consistent with 
previous studies we found that CAF-induced NETosis was ROS and PAD4-dependent 14, but 
in this case did not require G-CSF. 
 
With CAFs possessing such a potent effect on neutrophils via mechanisms distinct from 
previously described for systemic NETosis 21, we then examined the contribution of NETs in 
tumors. Inhibition of t-NETosis in mice with established tumors had no impact on neutrophil 
infiltration, yet was sufficient to abolish further growth. In these tumors, PAD4 inhibition 
translated to a skewing of neutrophils to a cytotoxic, pro-inflammatory and anti-tumor N1-like 
phenotype 19,56. Indeed, our data supported this hypothesis, confirming enhanced expression 
of activation markers and degranulation after PAD4 inhibition.   
 
We subsequently identified Amyloid β, a protein typically associated with neurodegenerative 
disorders, as the critical CAF-derived factor inducing t-NETs. Inhibition of Amyloid β or its 
proposed cognate receptor, CD11b 46, prevented CAF-mediated NETosis and reduced growth 
of established tumors. Moreover, addition of soluble Amyloid β exacerbated tumor growth 
further implicating NETosis as pathological response in the cancer context. With the observed 
increase in expression of CD11b on neutrophils after CAF CMed treatment, our data imply 
that CAFs not only secrete the Amyloid β to drive NETosis, but may also render the neutrophils 
more responsive to circulating Amyloid β in tumor-bearing animals through increased 
expression of its receptor 46. This is in line with reports that Amyloid β can induce ICAM-1 
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expression by endothelial cells suggesting that it may play additional roles in the high affinity 
capture of infiltrating neutrophils 41,57.  
 
In Alzheimer’s disease, Amyloid-driven NETosis has been associated with poor prognosis as 
a consequence of endothelial and parenchymal damage, and neurotoxicity 57–59. In this 
context, aggregation of Amyloid β not only drives the cognitive symptoms associated with 
Alzheimer’s, but its soluble form also acts as a DAMP contributing to the neuroinflammation 
which perpetuates progression 60,61. In cancer, we observed that Amyloid β secreted by CAFs 
form microaggregates in the tumor to drive NETosis in situ as well as disseminating into the 
blood where it conditions circulating and bone marrow resident neutrophils which raises the 
possibility that microaggregates of CAF-derived Amyloid β also act as a DAMP inducing 
aberrant NETosis to support tumor progression.  
 
We provide evidence that neutrophils in pancreatic, skin and lung cancers exposed to CAF-
derived cues exert pro-tumor effects that operate on multiple levels. Suppression of t-NETs in 
tumor bearing mice by inhibition of PAD4, or release of Amyloid β by BACE inhibition not only 
suppressed tumor growth but also brought about a decrease in thrombus formation as 
quantified by clotting factors; vWF and fibrinogen. With previous reports showing that NETs 
both contribute to thrombus formation, metastatic colonization and activation of dormant tumor 
cells 21–23,29,35 our findings that perturbation of either the driver or consequence of NETosis is 
sufficient to prevent tumor growth present the CAF-Amyloid-neutrophil axis as an attractive 
target. While the therapeutic potential of PAD4 blockade has yet to be clinically tested, it is 
possible that this approach may only provide a narrow therapeutic window since the inhibitor 
can acts when PAD4 is in a high calcium binding state 62, and may increase susceptibility to 
infection where NETosis is a critical response for bacterial clearance. Thus, inhibiting Amyloid 
β, for which drugs targeting BACE’s have already received FDA approval 63, and preventing 
neutrophils from receiving a NET stimulus may represent a more effective platform. 
Importantly, this would block pathological NETosis both at the primary tumor and systemically 
without impacting other critical neutrophil functions.  
 
With the growing body of evidence supporting a role for NETs in advanced cancer - metastatic 
colonization and recurrence 23,29,64, and clinical data linking neutrophil infiltration with poor 
prognosis in multiple cancer types 65–69 – our findings warrant further studies to determine 
whether Amyloid β (circulating, or in the primary tumor) can be used as a biomarker to stratify 
patients. Although, in neuroinflammatory conditions such as Alzheimer’s disease, circulating 
Amyloid β is not currently considered to be a biomarker reflective of levels in the cerebrospinal 
fluid and central nervous system 70, we reported a trend towards an increase in Amyloid β 
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levels in patients with melanoma compared to healthy volunteers. However, with our small 
cohort of archived patient samples, this was not significant. A number of external factors may 
be responsible for the observed variability; Circulating Amyloid β1-40 and β1-42 are 
predominantly bound to plasma proteins, and platelets or erythrocytes which can mask 
detection 70. Furthermore, differences in the hepatic and renal clearance of Amyloid β may 
influence the levels measured 70. Despite the difficulties in quantifying plasma Amyloid β 
levels, recent studies have implicated plasma Amyloid β in cancer. Higher levels of plasma 
Amyloid β were detected in hepatic cancer patients than those with Alzheimer’s disease 71, 
indicating that while cerebrospinal fluid levels are predictive of Alzheimer’s, circulating Amyloid 
β levels may be more reflective of cancer 71. Furthermore, it has been reported that breast and 
prostate tumor cells undergo amyloidosis as a result of environmental stress leading to cancer 
cell dormancy. This is particularly interesting in light of the recent study which implicated 
NETosis as a driver of dormant cancer cell activation in lung cancer 72. Indeed, amyloid 
accumulation in tumor cells may force the cells into a dormant state but as a consequence 
may also induce NETosis which could result in their activation and in a negative feedback 
system, re-initiation of the tumor. Amyloid β-induced NETosis drove tumor growth by 
reciprocally effecting CAFs, with t-NETs supporting proliferation and a more contractile 
phenotype. This phenomenon has also been reported in fibrosis where NETosis was found to 
drive activation, differentiation and the fibrotic response of human lung fibroblasts 18. 
Activation, matrix deposition and stiffening have all been correlated with disease progression 
and promotion of tumor growth in many cancers 1,4 without directly affecting tumor cell 
proliferation. Therefore, the direct action of Amyloid β on tumor cells previously reported 72 is 
distinct to the indirect effects it has on the tumor through the induction of NETosis further 
supporting a potential rationale for using BACE inhibitors to treat cancer.  
 
In summary, we have demonstrated the existence of a novel mechanism by which CAFs 
stimulate t-NETosis at local and systemic levels via production of Amyloid β. Targeting this 
process with existing small molecule inhibitors stops tumour growth and restores a pro-
inflammatory neutrophil phenotype. This sets the stage for further studies examining the 
potential of therapeutically targeting NETs.  
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All experiments involving animals were performed in accordance with 
UK Home Office regulations (PPL P88378375). For spontaneous genetic mouse tumors, 
Tyr::CreER; BrafCA; Ptenlox/lox (skin tumor) model, the LSL-
KrasG12D/+;LSLTp53R172H/+;Pdx-1-Cre (pancreatic tumor) model, and inducible 
LSLKrasG12D/+;p53LSL-R270H/ER (lung tumor) model systems were tested. Orthotopic 
syngeneic tumours using B16.F10 melanoma were performed in approximately 8-week-old 
female C57BL/6 mice. 
 
PAD4 inhibition in vivo  
Male and female mice were treated with PAD4 inhibitors; 3.5mM Cl-amidine (EMD Millipore), 
20mg/kg GSK484 (Cayman Chemicals) or a vehicle control (DMSO). Where possible, 
technicians performing the experiment were blinded to drug treatments. Mice were recruited 
when tumors reached between 3-6mm in diameter and then received I/P doses of PAD4 
inhibitor or vehicle control every day for 7d or until tumors reached their size limit. The size of 
pancreatic tumors was monitored by high-resolution ultrasound, as previously described 2. For 
skin tumors, the tumor volume was recorded daily using the formula (π/6)(shortest 
length*longest length)2.  After treatment, the cellularity of the tumours was determined by flow 
cytometric analysis of the number of cells present in the tumour after digestion of the tissue. 
The number of cells was then normalised to tumor size. Plasma was isolated from skin and 
pancreatic tumor-bearing mice by collecting the blood from cardiac puncture and centrifuging 
at 800g for 10min. Plasma was then snap frozen for measurements of analytes at a later 
stage.  
 
BACE inhibition in vivo  
Tumour-bearing Tyr::CreER; BrafCA; Ptenlox/lox  mice were treated with 5mg/kg BACE inhibitor 
(Z-VLL-CHO, Abcam) or vehicle control. Mice were recruited when tumors reached between 
3-6mm in diameter and then received I/P doses of BACE inhibitor for 7d or until tumors 
reached their size limit. Tumor volume was recorded daily using the formula (π/6)(shortest 
length*longest length)2. After treatment, the cellularity of the tumours was determined by flow 
cytometric analysis of the number of cells present in the tumour after digestion of the tissue. 
The number of cells was then normalised to tumor size. 
 
Amyloid β and CAF CMed treatment of tumors 
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2.5 x 105 B16.F10 melanoma cells were inoculated subcutaneously into the shoulder region. 
Where possible, technicians performing the experiment were blinded to drug treatments; At 
day 5, day 7 and day 9 mice received I/P infusion of either vehicle, CAF CMed or recombinant 
Amyloid β. The tumor volume was recorded daily using the formula (π/6)(shortest 
length*longest length)2. After 11 days or when the tumors reached the size limit, the mice were 
sacrificed. The immune landscape and CAF composition of the tumors was analysed by flow 
cytometry.  
 
CAF CMed treatment in vivo  
For investigations of CAF factors in vivo in the absence of tumors, CAF or FB CMed diluted 
1:1 in complete culture media or 250μg/ml recombinant amyloid β was I/V infused into 
C57BL/6 mice and the bone marrow was harvested 24h later.  
 
Cell isolation and culture 
CAFs were isolated from skin, lung (58) and pancreatic tumor bearing mice by mechanical 
separation of the tumor followed by digestion with an enzymatic cocktail consisting of 1mg/ml 
collagenase A and collagenase D and 0.4mg/ml DNase I (all from Roche) in PBS at 37°C for 
2-3h with rotation at 600rpm. 10mM EDTA was then added to stop the enzymatic reaction. 
Normal FBs were isolated from matched tissues of wild type mice using the same method. 
CAFs and normal FBs were maintained in RPMI (Sigma- Aldrich) with 1.5 g/L NaHCO3, 10% 
fetal bovine serum (Life Technologies), 1% penicillin-streptomycin (Sigma-Aldrich), 10mM 
HEPES (Gibco), 15μM β-mercaptoethanol (Sigma-Aldrich).  
 
Conditioned media generation and fractionation 
CMed from FB and CAFs was generated by culturing the cells until they reached 40-50% 
confluence and then changing the media to complete endothelial cell culture medium 
(Generon). The media was then harvested after 24h and filtered through 0.2um cell strainers 
before freezing. In some experiments, pancreatic or lung CAFs were treated with an inhibitor 
to beta-site Amyloid precursor protein cleaving enzyme 1 and 2 (BACE) (0.7μM; Abcam) for 
the duration of CAF CMed generation to inhibit Amyloid β production by the cells.  
 
CAF CMed was also separated into the metabolite (less than 3kDa) and protein (more than 
3kDa) fractions using 3kDa centrifugal filters (Merck Millipore) according to the manufacturer’s 
instructions. To isolate extracellular vesicles (MVs), CAF CMed was ultracentrifuged at 
100,000g for 90min. MV depleted CMed was collected and the isolated MVs were 
resuspended in complete culture media.  
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Neutrophil isolation  
Wild type male and female C57BL/6 mice were sacrificed by cervical dislocation. Femurs and 
tibias were removed and BM aspirate was collected. Neutrophils were isolated using a two-
step histopaque density gradient as previously described 73. Purified neutrophils were washed 
in PBS. To test the NETting capability of neutrophils from tumor bearing mice, bone marrow 
from mice bearing skin, lung and pancreatic tumors of varying size were isolated.  
 
NETosis assay 
Bone marrow-derived neutrophils were counted and seeded onto poly-D-lysine coated plates 
at a density of 1x105 cells per condition in serum free media. The media was changed to 
complete endothelial cell culture medium (Generon). To study NETosis, neutrophils were 
either treated with 1ug/ml Phorbol 12-myristate 13-acetate (PMA), CMed derived from FB or 
CAFs mixed 1:1 with complete culture media. Neutrophils were treated for 3h at 37°C and 5% 
CO2 and then stained with 20uM SYTOX™ Green Nucleic Acid Stain for 10min (Thermofisher 
Scientific). Images and videos were taken using a Zeiss Axio Observer.Z1 coupled with 
incubation chamber (ZEISS). 5 images were taken per well and each condition was performed 
in duplicate or triplicate. 
 
To test the effects of ROS on NETosis, neutrophils were treated with anti-oxidants; 10mM n-
acetyl cysteine (NAC), 20μM Diphenyleneiodonium (DPI), 2mM Trolox and 2mM Vitamin C 
for 30min prior to inducing NETosis and for the duration of the NET assay. Alternatively, 
neutrophils were treated with 0.03μg/ml α-G-CSF (R&D Systems) or 50μM Chloroquine 
(Sigma-Aldrich) for the duration of the NET assay. In some experimemts, neutrophils were 
treated with 1.5mg/ml Cl-amidine, an inhibitor of the Protein Arginine Deiminase 4 (PAD4), 
10μg/ml anti-CD11b or anti-TLR2 (Biolegend) or 1μg/ml fibronectin inhibitor (Santa-Cruz 
Biotechnology) for the duration of culture. The area of NET coverage was quantified using 
ZEN Lite (ZEISS) and ImageJ (Fiji) software by drawing around every NET within a field. Dead 
cells (positive for SYTOX green) were also counted per field.   
 
NET isolation and quantification 
After NET generation, neutrophils were treated with 1U/ml micrococcal nuclease (Sigma-
Aldrich) for 10min (found to be the optimum time for detaching NETs from neutrophils without 
digesting the NETting DNA) at 37°C and 5% CO2. The enzyme was inactivated with 0.5mM 
EDTA.   
 
Gel contraction assays 
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Pancreatic CAFs were treated with approximately 10ng/ml NETting DNA (taken from 1x105 
neutrophils stimulated with CAF CMed or PMA) for 24h or from untreated neutrophils. CAFs 
were trypsinized and then seeded into 2mg/ml collagen gels (Rat tail collagen, BD 
Biosciences) at a density of 1x105 cells/gel in 24 well plates. Gels were left to polymerise for 
20min at 37 °C before adding full media. The gel was detached from the culture dish using a 
pipette tip. The gels were imaged at 24h, 48h and 72h after generation. The area of the gel 
was then measured using ImageJ software. The relative gel area was then calculated by 




Tumors were minced using a razor and digested with 1mg/ml collagenase A and collagenase 
D and 0.4mg/ml DNase I in PBS at 37°C for 2h with rotation at 600rpm. 10mM EDTA was then 
added to stop the enzymatic reaction. The cell suspension was passed through a 70μm filter 
and stained with live/dead fixable violet stain (Thermofisher Scientific). Cells were 
subsequently stained with the following fluorescently conjugated antibodies; CD45 (30-F11), 
Ly6G (1A8), F4/80 (BM8), CD11b (M/170), CD11c (N418), Thy1 (30-H12), Podoplanin 
(8.1.1.), PDGFRα (APA5; all from Biolegend) and CD31 (390; eBioscience) at 1:300 dilution. 
Flow cytometry was performed on LSR Fortessa (BD Biosciences) analyzers. Unstained and 
single-stained compensation beads (Invitrogen) were run alongside to serve as controls. 
Offline analysis was carried out on FlowJo (Treestar). For in vivo PAD4 inhibitor studies, 
tumors were separated for flow cytometric and immunofluorescent analysis. Some GSK484 
treated tumors were too small for analysis and were therefore excluded (only tumor volumes 
were recorded).  
 
In vitro treatment of skin tumor cells with PAD4 inhibitors 
Tumor cells were isolated from skin tumors by digestion with 4mg/ml Collagenase A for 1h at 
37oC. The cells were then strained through a filter and seeded onto a culture dish in DMEM 
supplemented with 5% FBS and 1% penicillin/streptomycin. The cells were cultivated for 3-4d 
and then seeded onto 24-well plates at a density of 3x104 cells/well. The cells were either 
treated with DMSO (vehicle control), 100µM Cl-amidine or 10µM GSK484 for 48h. Images 
were taken at 0h, 24h and 48h after treatment.   
 
In vitro neutrophil staining 
Bone marrow neutrophils were isolated as described above and treated with lung FB or CAF 
CMed for 30min. Neutrophils were then treated with 10μM 2′,7′-Dichlorodihydrofluorescein 
diacetate (DCFDA; Sigma-Aldrich) or 2x108 yellow/green 1μm fluoresbrite beads 
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(Polysciences Inc.) for 20min. Alternatively, neutrophils were treated with CMed and stained 
with antibodies for CD11b (M/170), CD18 (M18/2) and CD62L (MEL-14; all from Biolegend). 
In some experiments, neutrophils were treated with CMed and stained with Annexin V (BD 
Pharmingen) and 7-AAD (Thermofisher Scientific) for 30min. For all experiments, the cells 
were washed and then immediately analyzed by flow cytometry. 
 
PAD4 inhibitor treatment on neutrophil function in vitro 
Murine bone marrow neutrophils were seeded at 1x105 cells per condition in complete 
endothelial cell culture medium mixed 1:1 with pancreatic CAF CMed. Neutrophils were 
treated with or without 1.5mg/ml Cl-amidine for 3h. Neutrophil activation was then assessed 
by measuring expression of CD11b, CD18 and CD62L. ROS production was assessed 
by measuring DCFDA by flow cytometry (as above). The phagocytic activity of the neutrophils 
was assessed by measuring fluorescent bead uptake by flow cytometry. Neutrophil 
degranulation was determined by surface expression of CD35 and CD63. 
 
Characterization of CAFs and FB 
Isolated CAFs and FB were stained for typical markers; Podoplanin, PDGFRα and Thy1 (as 
described above) and markers to exclude immune cells (CD45), endothelial cells (CD31) and 
epithelial cells (EpCAM clone G8.8; all from Biolegend). 
 
Gene expression analysis 
Pancreatic CAFs were treated with approximately 10ng/ml NETting DNA (from CAF CMed or 
PMA stimulated neutrophils) for 24h. RNA was isolated using the RNeasy Mini Kit (Qiagen, 
Crawley, UK), converted to cDNA and analyzed by qPCR using Universal PCR mastermix 
(Life Technologies) according to manufacturer’s instructions. Primers were bought as Assay 
on Demand kits from Applied Biosystems. qRT-PCR was performed using TaqMan assays 
(Col1a2 Mm00483888_m1, Acta2 Mm00725412_s1 and Gapdh Mm99999915_g1) and a 
StepOne Real Time PCR System (both Life Technologies). Levels of each gene was 
expressed as 2-ΔCT (relative to Gapdh). 
 
Analysis of Amyloid-related genes in human tumors 
Expression of app and bace2 and correlations with CAF and lymphatic markers in pancreatic 
adenocarcinoma and skin cutaneous melanoma compared to healthy tissue were analyzed 
using GEPIA RNA-sequencing expression data taken from the TCGA and GTEx projects 74.  
 
Immunofluorescence 
Tumors were snap frozen in OCT medium (TissueTek). 5-7µm sections were fixed in ice cold 
acetone/methanol for 5min. Sections were blocked in 10% donkey serum in PBS and 
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incubated with primary antibodies overnight at 4°C. Primary antibodies as follows: Rabbit anti-
citrullinated histone H3 R17+R2+R8 (ab5103, 1:500, Abcam), goat anti-myeloperoxidase 
(AF3667, 1:1000, RnD Systems), hamster anti-podoplanin (clone 8.1.1, 127402, 1:100, 
BioLegend), Alexa 488 conjugated mouse anti-APP (clone 22C11, MAB348A4, 1:100, Merck-
Millipore), mouse anti-αSMA (clone 1A4, MAB1420, 1:100, RnD Systems). Slides were 
washed, incubated with appropriate secondary antibodies and counterstained with DAPI. 
Sections were mounted in Slowfade Gold (Invitrogen). Images were acquired on a Leica SP5 
confocal microscope.  
 
Paraffin-embedded formalin fixed human pancreatic TMA slides (Biomax) (LREC HBREC 
2019.16) were dewaxed in xylene and rehydrated in graded alcohols prior to antigen retrieval 
in Tris-EDTA pH9. Slides were blocked and incubated with primary antibodies as above at 
4°C overnight. Samples were washed and incubated in fluorescently conjugated secondary 
antibodies before cell nuclei were counterstained with DAPI and sections were mounted in 
Slowfade Gold and imaged on the Leica SP5. 
 
ELISA 
Levels of murine Amyloid β42, (Fisher Scientific), von Willebrand factor (vWF) and fibrinogen 
(both from Abcam) were measured in plasma collected from skin and pancreatic tumor bearing 
mice or in serum-free CMed from pancreatic CAFs as per manufacturer’s instructions. Human 
platelet poor plasma was obtained by centrifuging whole blood from healthy donors at 2000g 
for 15min. Samples were immediately snap frozen until use. Archived plasma samples were 
obtained from melanoma patients (MELRESIST NRES: 11.NE.0312). Levels of Amyloid β42, 
von Willebrand factor (vWF) and fibrinogen (all from Abcam) in human melanoma patients 
and healthy controls was assessed as per manufacturers guidelines.  
 
Mass spectrometry 
FB and CAF CMed were generated without fetal bovine serum for 24h. The protein fractions 
were isolated and concentrated using 3kDa centrifugal filters (Merck Millipore). LC MS/MS 
was performed on the concentrated culture CMed and spectral analysis was performed. Data 
was analyzed using Scaffold 4 software.  
 
Measurement of NETs or NET CM on cells in vitro 
NETs: 1x105 neutrophils were treated with CAF CMed diluted 1:1 in complete EC media (Cell 
Biologics) with or without Cl-amidine and incubated for 3h to generate NETs. The media was 
then harvested from the NETting or NET inhibited neutrophils. PBS supplemented with 1U/ml 
micrococcal nuclease (Sigma-Aldrich) was then added to the neutrophils for 10min at 37°C 
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and 5% CO2 to detach the NETs. The enzyme was inactivated with 0.5mM EDTA.  PBS 
containing the NETs was then harvested for xCELLigence assays. 
 
Neutrophil-derived factors: As for above, media from NETting or NET inhibited neutrophils 
was harvested for xCELLigence assays. Pancreatic CAF or tumour cells were seeded onto 
16 well E-plates (ACEA Biologics) at a density of 5x103 cells/well. Cells were allowed to adhere 
for 1h. The media was then replaced with the NETting or NET inhibited neutrophil conditioned 
media or the corresponding NETs. Plates were placed into an xCELLigence RTCA MP Real 
Time Cell Analyzer (ACEA Biologics). Recordings of the impedance, correlating to cell 
proliferation, were then taken over a 48h period. The background was then subtracted from 
the appropriate wells.  
 
Statistical analysis 
Data are expressed as mean ± SEM, where a different neutrophil isolate and batch of CMed 
was used for each experiment. Multi-variant data were analyzed using analysis of variance 
(ANOVA), followed by Dunnett or Tukey post-hoc tests. Mann-Whitney or t-test was used to 
compare individual treatment conditions. p<0.05 was considered statistically significant. For 
mass spectrometry, differences in protein expression in FB and CAF CMed was considered 
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Figure legends 
Fig. 1. CAF-derived factors induce NETosis in vitro and in vivo. (A) Confocal microscopy of 
myeloperoxidase (MPO) and podoplanin (PDPN) expressed on neutrophils and CAFs 
respectively in pancreatic and skin tumors. (B) Confocal microscopy of NETs in murine 
pancreatic and skin tumors showing expression of myeloperoxidase (MPO) and Citrullinated 
histone H3 (CitH3) by NETting neutrophils and podoplanin (PDPN) by CAFs. (C) 
Quantification of the area of the field covered by SYTOX green positive neutrophil-derived 
extracellular DNA relative to the number of neutrophils in each field after treatment with 
pancreatic, lung or skin FBs CMed, CAF CMed or PMA for 3h. (D) The percentage of dead 
neutrophils after treatment with pancreatic, lung or skin CAF CMed or PMA based on the 
number of SYTOX green positive neutrophils. (E) Confocal microscopy of bone marrow 
neutrophils stained with MPO, CitH3 and live/dead cell viability dye after induction of NETosis 
by treatment with CAF CMed for 3h. Quantification of the relative NET coverage of neutrophils 
treated with CAF CMed with or without pre-treatment with (F) N-acetyl-cysteine (NAC) or (G) 
anti-granulocyte colony stimulating factor (α-GCSF). Data are mean ± SEM; * = p<0.05, ** = 
p<0.01 and *** = p<0.001 using t-test. Assays were performed on (C) n=3-10, (D) n=4, (F) 
n=4-5 and (G) n=4 independent experiments. Scale bars are 50µm. 
 
Fig. 2. CAF-derived factors drive NETosis systemically. Quantification of (A) relative NET 
coverage and (B) relative number of bone marrow neutrophils taken from mice with 
pancreatic, lung or skin tumors. Quantification of the (C) relative NET coverage and (D) 
relative number of bone marrow neutrophils isolated from wild type mice intravenously 
infused with pancreatic or lung FB or CAF CMed 24h before analysing NETosis. (E) 
Quantification of relative NET coverage after stimulation with pancreatic CAF CMed with or 
without treatment with Cl-amidine in vitro. (F) Quantification of the relative NET coverage 
and (G) relative number of bone marrow neutrophils isolated from mice intravenously 
infused with lung CAF CMed with or without pre-treatment with Cl-amidine for 24h. Data are 
mean ± SEM; * = p<0.05, ** = p<0.01 and *** = p<0.001 using (A and F) t-test and (C-E) 
one-way ANOVA with a Dunnett post hoc test. Assays were performed on (A-B) n=4 (in 
duplicate), n=7 (in quadruplet) and n=7 for pancreatic, lung and skin tumor bearing mice 
respectively, (C-D) n=8 (in triplicate) and n=6-16 (in duplicate) for pancreatic and lung FB 
and CAF CMed infused mice respectively, (E) n=3 (in triplicate) and (F-G) n=8 (in triplicate) 
independent experiments. 
 
Fig. 3. Inhibiting t-NETosis stops tumor growth in vivo. (A) Schematic of GSK484 treatment 
regime of skin tumor bearing mice. (B) Relative volume of skin tumors on mice treated with 
vehicle or GSK484 over 8d. (C) Flow cytometric analysis of the percentage immune cells 
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(CD45+), myeloid cells (CD11b+), macrophages (F4/80+) and neutrophils (Ly6G+) in the 
tumor. (D) Representative confocal images showing neutrophils (myeloperoxidase (MPO) in 
green) within the tumor in control or treated animals (zoomed inset). Nuclei counterstained 
with DAPI (white). (E) The levels of clotting factors (fibrinogen and von Willebrand factor; 
vWF) in the plasma of skin tumor bearing mice treated with vehicle or GSK484. (F) 
Quantification of CD11b, CD18 and CD62L expression on wild type bone marrow-derived 
neutrophils after 3h treatment with pancreatic CAF CMed, with and without Cl-amidine, in 
vitro by flow cytometry. (G) The phagocytic capacity of wild type bone marrow-derived 
neutrophils after 3h pancreatic CAF CMed, with and without Cl-amidine, treatment based on 
uptake of fluorescent 1µm beads in vitro assessed by flow cytometry. (H) Quantification of 
ROS production by wild type bone marrow-derived neutrophils after 3h treatment with 
pancreatic CAF CMed, with and without Cl-amidine, in vitro based on the levels of DCFDA 
by flow cytometry. (I) Quantification of neutrophil degranulation based on CD35 and CD63 
expression by flow cytometry after 3h pancreatic CAF CMed, with and without Cl-amidine for 
3h. (J) Representative plot illustrating tumor cell growth following treatment with PAD4i-
treated neutrophil derived media. Data are mean ± SEM; * = p<0.05, ** = p<0.01and *** = 
p<0.001 using (B and E) a Mann-Whitney test and (F-I) a one-way ANOVA with a Tukey 
post hoc test. Assays were performed on (B) n=7-8, (C and E) n=4-7, (F-I) n=3 (in triplicate) 
and (J) Representative of n=2 (in duplicate) independent experiments. Scale bars are 
100µm. 
 
Fig. 4. Amyloid β is the driver of CAF-induced t-NETosis. (A) Quantification of the relative 
NET coverage of neutrophils that were added to lung CAFs treated with or without FB 
CMed, CAF CMed or PMA for 3h. (B) Quantification of the relative NET coverage of 
neutrophils treated with lung CAF CMed or CAF CMed-derived microvesicles (MV) or CMed 
depleted of MV. (C) Quantification of the relative NET coverage of neutrophils treated with 
lung CAF CMed or the metabolite or protein fractions of the CAF CMed. (D) Differentially 
secreted proteins in pancreatic FB and CAF CMed analyzed by mass spectrometry. (E) 
Spectral counts for NET-related factors secreted by pancreatic FBs and CAFs. (F) Levels of 
Amyloid β in basal media and pancreatic CAF CMed. (G) Confocal microscopy of amyloid 
precursor protein (APP) and Podoplanin (PDPN) expressed by CAFs in pancreatic tumors. 
Insets depict diffuse vs. aggregated patterns of APP/Amyloid β distribution. (H) 
Quantification of the relative NET coverage of neutrophils treated with pancreatic and lung 
CAF CMed generated with or without 24h pre-treatment of the CAFs with a β-secretase 1 
and 2 (BACE1-2) inhibitor. (I) Quantification of the relative NET coverage of bone marrow 
neutrophils taken from wild type mice intravenously infused with pancreatic CAF CMed 
taken from cells treated with or without BACE1-2 inhibitor for 24h or recombinant Amyloid β. 
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(J) Schematic of BACEi treatment regime of skin tumor bearing mice and relative volume of 
skin tumors on mice before and after treatment with vehicle or Z-VLL-CHO. (K) Growth of 
orthotopically implanted B16.F10 tumor cells with vehicle, CAF CMed or recombinant 
Amyloid β treatment. Quantification of the relative NET coverage after 3h treatment with 
pancreatic CAF CMed with or without (L) CD11b or (M) TLR2 blocking antibodies. Data are 
mean ± SEM; ** = p<0.01 and *** = p<0.001 using (A and H) one-way ANOVA with a 
Dunnett post hoc test, (B-C, E, I and J) t-test and (L-M) one-way ANOVA with a Tukey post 
hoc test. Assays were performed on (A) n=3-6, (B) n=7, (C) n=5, (E) n=3, (F) n=1-3, (H) n=6 
(in triplicate), (I) n=7 (in duplicate or triplicate), (J) n=7-9, (K) n=6 and (L-M) n=3 (in triplicate) 
independent experiments. Scale bars are 50µm. 
 
Fig. 5. t-NETs induce CAF activation. (A) Representative plot illustrating growth of CAFs in 
the presence of vehicle or micrococcal nuclease detached NETs. (B) Phase contrast images 
and respective quantification of the percentage area of cell free space per field after 
treatment of pancreatic FBs or CAFs with NETs derived from CAF CMed treated neutrophils 
for 24h. (C) Quantification of the size of collagen gels 24h, 48h and 72h after seeding 
pancreatic CAFs treated with or without NETs derived from CAF CMed treated neutrophils 
for 24h. (D) Expression of Acta2 and Col1a2 at the gene level in pancreatic CAFs treated 
with or without NETs derived from CAF CMed treated neutrophils for 24h. (E) Confocal 
microscopy of Collagen1 and phalloidin on pancreatic CAFs treated with or without NETs 
derived from unstimulated neutrophils or CAF CMed treated neutrophils for 24h. (F) 
Cellularity of melanoma after treatment with GSK484, Cl-amidine, BACEi or vehicle 
expressed as cells per unit volume. (G) Representative confocal image of nuclei and 
collagen after treatment with GSK484, Cl-amidine, or vehicle. Tissues stained with Herovici 
stain to demark new collagen (blue) vs. mature collagen (pink). (H) Representative plot 
illustrating growth of CAFs following treatment with CAF CMed or CAF CMed and PAD4i-
treated neutrophil-derived media. Data are mean ± SEM; * = p<0.05 and *** = p<0.001 using 
t-test. Assays were performed on (A and H) Representative of n=2 (in duplicate), (B) n=3 (in 
triplicate), (C) n=3 (in duplicate or quadruple), (D) n=4 (in duplicate) and (F) n=5-10 
independent experiments. Scale bars are 50µm (B and D), 500µm (G upper panel) and 
100µm (G upper panel). 
 
Fig. 6. Conservation of t-NETs in human disease. (A) Representative confocal images of 
NETting neutrophils and CAFs in human pancreatic tumor biopsies (MPO, green; CitH3, red; 
podoplanin, blue; DAPI, white). (B) Representative confocal images of NETting neutrophils 
and CAFs in human melanoma primar tumor and metastasis samples (MPO, green; CitH3, 
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red; podoplanin, blue; DAPI, white). (C) Median expression of app in human pancreatic 
adenocarcinoma and cutaneous melanoma compared to normal tissue from healthy donors 
and (D) Median expression of bace2 in human pancreatic adenocarcinoma and cutaneous 
melanoma compared to normal tissue from healthy donors (GTEx and TCGA datasets). (E) 
Correlation of app and bace2 with a lymphatic marker (lyve1) and CAF markers (pdpn, 
acta2, col1a2 and cd34). Kaplin-meier curves showing overall survival of pancreatic 
adenocarcinoma and cutaneous melanoma patients correlated with high and low expression 
of (F) bace2 or (G) app. 
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Collagen alpha−1(I) chain OS=Mus musculus GN=Col1a1 PE=1 SV=4
Serum albumin OS=Bos taurus GN=ALB PE=1 SV=4
Collagen alpha−2(I) chain OS=Mus musculus GN=Col1a2 PE=1 SV=2
Collagen alpha−1(III) chain OS=Mus musculus GN=Col3a1 PE=1 SV=4
Collagen, type VI, alpha 3 OS=Mus musculus GN=Col6a3 PE=1 SV=2
Fibronectin OS=Mus musculus GN=Fn1 PE=1 SV=1
Trypsin OS=Sus scrofa PE=1 SV=1
Collagen alpha−1(VI) chain OS=Mus musculus GN=Col6a1 PE=1 SV=1
Collagen alpha−1(V) chain OS=Mus musculus GN=Col5a1 PE=1 SV=2
Collagen alpha−2(V) chain OS=Mus musculus GN=Col5a2 PE=1 SV=1
Fibulin−2 OS=Mus musculus GN=Fbln2 PE=1 SV=2
Procollagen C−endopeptidase enhancer 1 OS=Mus musculus GN=Pcolce PE=1 SV=1
Actin, cytoplasmic 1 OS=Mus musculus GN=Actb PE=1 SV=1
Laminin subunit gamma−1 OS=Mus musculus GN=Lamc1 PE=1 SV=1
Periostin OS=Mus musculus GN=Postn PE=1 SV=2
Pigment epithelium−derived factor OS=Mus musculus GN=Serpinf1 PE=1 SV=2
Vimentin OS=Mus musculus GN=Vim PE=1 SV=3
Collagen alpha−1(XII) chain OS=Mus musculus GN=Col12a1 PE=1 SV=1
Osteopontin OS=Mus musculus GN=Spp1 PE=1 SV=1
Peptidyl−prolyl cis−trans isomerase OS=Mus musculus GN=Ppia PE=1 SV=1
Basement membrane−specific heparan sulfate proteoglycan core protein OS=Mus musculus GN=Hspg2 PE=1 SV=1
Adipocyte enhancer−binding protein 1 OS=Mus musculus GN=Aebp1 PE=1 SV=1
Laminin subunit beta−1 OS=Mus musculus GN=Lamb1 PE=1 SV=1
Calumenin OS=Mus musculus GN=Calu PE=1 SV=1
Heat shock protein HSP 90−beta OS=Mus musculus GN=Hsp90ab1 PE=1 SV=3
Collagen alpha−2(VI) chain OS=Mus musculus GN=Col6a2 PE=1 SV=3
Collagen alpha−1(IV) chain OS=Mus musculus GN=Col4a1 PE=1 SV=1
Collagen alpha−2(IV) chain OS=Mus musculus GN=Col4a2 PE=1 SV=4
Heat shock cognate 71 kDa protein OS=Mus musculus GN=Hspa8 PE=1 SV=1
Fructose−bisphosphate aldolase A OS=Mus musculus GN=Aldoa PE=1 SV=2
SPARC OS=Mus musculus GN=Sparc PE=1 SV=1
Filamin, alpha OS=Mus musculus GN=Flna PE=1 SV=1
Insulin−like growth factor−binding protein 7 OS=Mus musculus GN=Igfbp7 PE=1 SV=1
Extracellular matrix protein 1 OS=Mus musculus GN=Ecm1 PE=1 SV=2
Thrombospondin 1 OS=Mus musculus GN=Thbs1 PE=1 SV=1
Prothymosin alpha OS=Mus musculus GN=Ptma PE=1 SV=2
Laminin subunit alpha−4 OS=Mus musculus GN=Lama4 PE=1 SV=2
Laminin subunit alpha−5 OS=Mus musculus GN=Lama5 PE=1 SV=4
Follistatin−related protein 1 OS=Mus musculus GN=Fstl1 PE=1 SV=2
Clusterin OS=Mus musculus GN=Clu PE=1 SV=1
Carboxypeptidase E OS=Mus musculus GN=Cpe PE=1 SV=2
Nidogen−1 OS=Mus musculus GN=Nid1 PE=1 SV=2
Cationic trypsin OS=Bos taurus PE=1 SV=3
Myosin−9 OS=Mus musculus GN=Myh9 PE=1 SV=4
Nucleobindin−1 OS=Mus musculus GN=Nucb1 PE=1 SV=2
Versican core protein OS=Mus musculus GN=Vcan PE=1 SV=1
Ceruloplasmin OS=Mus musculus GN=Cp PE=1 SV=1
Elongation factor 2 OS=Mus musculus GN=Eef2 PE=1 SV=2
Phosphoglycerate kinase 1 OS=Mus musculus GN=Pgk1 PE=1 SV=4
Syndecan−4 OS=Mus musculus GN=Sdc4 PE=1 SV=1
Pyruvate kinase PKM OS=Mus musculus GN=Pkm PE=1 SV=4
Thrombospondin−2 OS=Mus musculus GN=Thbs2 PE=1 SV=2
AHNAK nucleoprotein (desmoyokin) OS=Mus musculus GN=Ahnak PE=1 SV=1
Annexin A1 OS=Mus musculus GN=Anxa1 PE=1 SV=2
Moesin OS=Mus musculus GN=Msn PE=1 SV=3
Amyloid beta A4 protein OS=Mus musculus GN=App PE=1 SV=3
Prelamin−A/C OS=Mus musculus GN=Lmna PE=1 SV=2
Tropomyosin alpha−4 chain OS=Mus musculus GN=Tpm4 PE=1 SV=3
Protein disulfide−isomerase A3 OS=Mus musculus GN=Pdia3 PE=1 SV=2
Peptidyl−prolyl cis−trans isomerase B OS=Mus musculus GN=Ppib PE=1 SV=2
Myristoylated alanine−rich C−kinase substrate OS=Mus musculus GN=Marcks PE=1 SV=2
Latent−transforming growth factor beta−binding protein 1 OS=Mus musculus GN=Ltbp1 PE=1 SV=2
14−3−3 protein epsilon OS=Mus musculus GN=Ywhae PE=1 SV=1
Ubiquitin−40S ribosomal protein S27a OS=Homo sapiens GN=RPS27A PE=1 SV=2
Caldesmon 1 OS=Mus musculus GN=Cald1 PE=1 SV=1
14−3−3 protein zeta/delta OS=Mus musculus GN=Ywhaz PE=1 SV=1
Nucleolin OS=Mus musculus GN=Ncl PE=1 SV=2
Collagen alpha−1(XVIII) chain OS=Mus musculus GN=Col18a1 PE=1 SV=1
Tropomyosin alpha−1 chain OS=Mus musculus GN=Tpm1 PE=1 SV=1
Protein disulfide−isomerase OS=Mus musculus GN=P4hb PE=1 SV=2
Insulin−like growth factor−binding protein 6 OS=Mus musculus GN=Igfbp6 PE=2 SV=2
Alpha actinin 1a OS=Mus musculus GN=Actn1 PE=1 SV=1
Endoplasmin OS=Mus musculus GN=Hsp90b1 PE=1 SV=2
Fibrillin−1 OS=Mus musculus GN=Fbn1 PE=1 SV=2
Metalloproteinase inhibitor 2 OS=Mus musculus GN=Timp2 PE=1 SV=2
Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6
Elongation factor 1−alpha 1 OS=Mus musculus GN=Eef1a1 PE=1 SV=3
Alpha−enolase OS=Mus musculus GN=Eno1 PE=1 SV=3
78 kDa glucose−regulated protein OS=Mus musculus GN=Hspa5 PE=1 SV=3
Neutral alpha−glucosidase AB OS=Mus musculus GN=Ganab PE=1 SV=1
Gremlin−1 OS=Mus musculus GN=Grem1 PE=2 SV=1
Plectin OS=Mus musculus GN=Plec PE=1 SV=3
Connective tissue growth factor OS=Mus musculus GN=Ctgf PE=2 SV=3
Complement C3 OS=Mus musculus GN=C3 PE=1 SV=3
Low−density lipoprotein receptor OS=Mus musculus GN=Ldlr PE=1 SV=1
Mesothelin OS=Mus musculus GN=Msln PE=1 SV=1
Protein SET (Fragment) OS=Mus musculus GN=Set PE=1 SV=1
Peptidyl−prolyl cis−trans isomerase C OS=Mus musculus GN=Ppic PE=1 SV=1
Peroxiredoxin−1 (Fragment) OS=Mus musculus GN=Prdx1 PE=1 SV=8
Tubulin alpha−1B chain OS=Mus musculus GN=Tuba1b PE=1 SV=2
Out at first protein homolog OS=Mus musculus GN=Oaf PE=2 SV=1
Cathepsin L1 OS=Mus musculus GN=Ctsl PE=1 SV=2
Transgelin−2 OS=Mus musculus GN=Tagln2 PE=1 SV=4
Vinculin OS=Mus musculus GN=Vcl PE=1 SV=4
Sulfhydryl oxidase 1 OS=Mus musculus GN=Qsox1 PE=1 SV=1
Decorin OS=Mus musculus GN=Dcn PE=1 SV=1
Annexin (Fragment) OS=Mus musculus GN=Anxa2 PE=1 SV=1
Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6
Nucleoside diphosphate kinase OS=Mus musculus GN=Gm20390 PE=3 SV=1
Serpin H1 OS=Mus musculus GN=Serpinh1 PE=1 SV=3
Protein CYR61 OS=Mus musculus GN=Cyr61 PE=1 SV=1
L−lactate dehydrogenase OS=Mus musculus GN=Ldha PE=1 SV=1
Filamin−B OS=Mus musculus GN=Flnb PE=1 SV=3
Tropomyosin alpha−3 chain OS=Mus musculus GN=Tpm3 PE=1 SV=1
Cathepsin B OS=Mus musculus GN=Ctsb PE=1 SV=2
DNA segment, Chr 6, Wayne State University 176, expressed, isoform CRA_a OS=Mus musculus GN=Fam3c PE=1 SV=1
Matrilin−2 OS=Mus musculus GN=Matn2 PE=1 SV=1
Transgelin OS=Mus musculus GN=Tagln PE=1 SV=3
Biglycan OS=Mus musculus GN=Bgn PE=1 SV=1
Cadherin−2 OS=Mus musculus GN=Cdh2 PE=1 SV=2
Transitional endoplasmic reticulum ATPase OS=Mus musculus GN=Vcp PE=1 SV=4
T−complex protein 1 subunit theta OS=Mus musculus GN=Cct8 PE=1 SV=3
Collagen alpha−1(XI) chain OS=Mus musculus GN=Col11a1 PE=1 SV=2
Proliferation−associated protein 2G4 OS=Mus musculus GN=Pa2g4 PE=1 SV=3
Immunoglobulin superfamily containing leucine−rich repeat protein OS=Mus musculus GN=Islr PE=1 SV=1
60S ribosomal protein L7 (Fragment) OS=Mus musculus GN=Rpl7 PE=1 SV=1
Heat shock protein HSP 90−alpha OS=Mus musculus GN=Hsp90aa1 PE=1 SV=4
14−3−3 protein theta (Fragment) OS=Mus musculus GN=Ywhaq PE=1 SV=1
Semaphorin−3C OS=Mus musculus GN=Sema3c PE=1 SV=2
Alpha−actinin−4 OS=Mus musculus GN=Actn4 PE=1 SV=1
Collagen alpha−1(II) chain OS=Mus musculus GN=Col2a1 PE=1 SV=2
Uncharacterized protein OS=Mus musculus GN=Rpl7a−ps3 PE=4 SV=1
Insulin−like growth factor−binding protein 4 OS=Mus musculus GN=Igfbp4 PE=1 SV=2
Transketolase OS=Mus musculus GN=Tkt PE=1 SV=1
Tropomyosin beta chain OS=Mus musculus GN=Tpm2 PE=1 SV=1
Exostosin−2 OS=Mus musculus GN=Ext2 PE=1 SV=2
Calsyntenin−1 OS=Mus musculus GN=Clstn1 PE=1 SV=1
Protein−lysine 6−oxidase OS=Mus musculus GN=Lox PE=1 SV=1
60S ribosomal protein L12 OS=Mus musculus GN=Rpl12 PE=1 SV=2
Platelet−activating factor acetylhydrolase OS=Mus musculus GN=Pla2g7 PE=2 SV=2
Syndecan−1 OS=Mus musculus GN=Sdc1 PE=1 SV=1
Malate dehydrogenase, cytoplasmic OS=Mus musculus GN=Mdh1 PE=1 SV=3
Peroxidasin homolog OS=Mus musculus GN=Pxdn PE=1 SV=1
40S ribosomal protein S9 OS=Mus musculus GN=Rps9 PE=1 SV=3
Elongation factor 1−delta OS=Mus musculus GN=Eef1d PE=1 SV=1
Lipoprotein lipase OS=Mus musculus GN=Lpl PE=1 SV=3
Histone H1.4 OS=Mus musculus GN=Hist1h1e PE=1 SV=2
40S ribosomal protein SA OS=Mus musculus GN=Rpsa PE=1 SV=4
40S ribosomal protein S3 OS=Mus musculus GN=Rps3 PE=1 SV=1
Rho GDP−dissociation inhibitor 1 OS=Mus musculus GN=Arhgdia PE=1 SV=3
Amyloid−like protein 2 OS=Mus musculus GN=Aplp2 PE=1 SV=4
Procollagen−lysine,2−oxoglutarate 5−dioxygenase 1 OS=Mus musculus GN=Plod1 PE=1 SV=1
Protein NOV homolog OS=Mus musculus GN=Nov PE=1 SV=1
Heat shock 70 kDa protein 4 OS=Mus musculus GN=Hspa4 PE=1 SV=1
Metalloproteinase inhibitor 1 OS=Mus musculus GN=Timp1 PE=1 SV=2
Heterogeneous nuclear ribonucleoprotein A/B OS=Mus musculus GN=Hnrnpab PE=1 SV=1
Adenosylhomocysteinase OS=Mus musculus GN=Ahcy PE=1 SV=3
Hsc70−interacting protein OS=Mus musculus GN=St13 PE=1 SV=1
Triosephosphate isomerase OS=Mus musculus GN=Tpi1 PE=1 SV=4
T−complex protein 1 subunit gamma OS=Mus musculus GN=Cct3 PE=1 SV=1
Heterogeneous nuclear ribonucleoprotein K OS=Mus musculus GN=Hnrnpk PE=1 SV=1
Tubulointerstitial nephritis antigen−like OS=Mus musculus GN=Tinagl1 PE=1 SV=1
Inter−alpha trypsin inhibitor, heavy chain 2 OS=Mus musculus GN=Itih2 PE=1 SV=1
Tubulin beta−5 chain OS=Mus musculus GN=Tubb5 PE=1 SV=1
Fibulin−1 OS=Mus musculus GN=Fbln1 PE=1 SV=2
45 kDa calcium−binding protein OS=Mus musculus GN=Sdf4 PE=1 SV=1
Proprotein convertase subtilisin/kexin type 9 OS=Mus musculus GN=Pcsk9 PE=1 SV=2
60S ribosomal protein L13 OS=Mus musculus GN=Rpl13 PE=1 SV=3
Rab GDP dissociation inhibitor beta OS=Mus musculus GN=Gdi2 PE=1 SV=1
Valine−−tRNA ligase (Fragment) OS=Mus musculus GN=Vars PE=1 SV=1
60S acidic ribosomal protein P2 OS=Mus musculus GN=Rplp2 PE=1 SV=3
Eukaryotic translation initiation factor 4B OS=Mus musculus GN=Eif4b PE=1 SV=1
Angiopoietin−related protein 4 OS=Mus musculus GN=Angptl4 PE=2 SV=1
60S ribosomal protein L4 OS=Mus musculus GN=Rpl4 PE=1 SV=3
High mobility group protein B1 OS=Mus musculus GN=Hmgb1 PE=1 SV=1
Receptor−type tyrosine−protein phosphatase kappa OS=Mus musculus GN=Ptprk PE=1 SV=1
Angiotensin−converting enzyme (Fragment) OS=Mus musculus GN=Ace PE=1 SV=1
Fascin OS=Mus musculus GN=Fscn1 PE=1 SV=4
Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Mus musculus GN=Hnrnpa2b1 PE=1 SV=2
Protein disulfide−isomerase A6 OS=Mus musculus GN=Pdia6 PE=1 SV=1
Myosin regulatory light chain 12B OS=Mus musculus GN=Myl12b PE=1 SV=2
Malate dehydrogenase, mitochondrial OS=Mus musculus GN=Mdh2 PE=1 SV=3
Golgi apparatus protein 1 (Fragment) OS=Mus musculus GN=Glg1 PE=1 SV=1
40S ribosomal protein S8 OS=Mus musculus GN=Rps8 PE=1 SV=2
Neural cell adhesion molecule 1 OS=Mus musculus GN=Ncam1 PE=1 SV=1
Proliferating cell nuclear antigen OS=Mus musculus GN=Pcna−ps2 PE=3 SV=1
Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2
Glucosidase 2 subunit beta OS=Mus musculus GN=Prkcsh PE=1 SV=1
Latent−transforming growth factor beta−binding protein 3 OS=Mus musculus GN=Ltbp3 PE=1 SV=1
40S ribosomal protein S11 OS=Mus musculus GN=Rps11 PE=1 SV=1
Adenylosuccinate synthetase isozyme 2 OS=Mus musculus GN=Adss PE=1 SV=2














































































































































Amyloid β A4 protein Fibronectin HSP90
G.















































































































































































































































3 ) Basal media
CAF CMed




















3 ) Basal media
rAmyloid β

















3 ) Basal media
CAF CMed










































































































































































































































































.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 



















































































































































































































































eut + PAD4i media
Media
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































MPO CitH3 PDPN DAPI

















































































MPO CitH3 PDPN DAPI
Figure 6
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted January 11, 2020. ; https://doi.org/10.1101/2020.01.10.901686doi: bioRxiv preprint 
